myelodysplastic syndromes/seizures

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 24 rezilta yo

The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS).

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

One hundred and sixteen (116) anaemic patients with myelodysplastic syndromes (MDS) were treated with recombinant human erythropoietin (r-HuEpo) in an open-label, multicentre, compassionate treatment trial; 100 patients received therapy for > or = 4 weeks and were evaluable for efficacy. The

A case of posterior reversible encephalopathy syndrome in a child with myelodysplastic syndrome following allogenic bone marrow transplantation.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Posterior reversible encephalopathy syndrome (PRES) is an uncommon but distinctive clinical-radiologic entity characterized by headache, seizures, visual disturbance, and altered mental function associated with reversible white matter edema affecting the posterior parietal and occipital lobes of the

Myelodysplastic syndrome associated with chronic valproic acid therapy: a case report and review of the literature.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This report is of a case of myelodysplastic syndrome occurring in a 63 year old female on long-term valproic acid therapy for seizure disorder. Valproic acid therapy is widely prescribed for seizure disorders and is often associated with thrombocytopenia, macrocytic anemia and a reversible

Rapidly progressive toxic leukoencephalomyelopathy with myelodysplastic syndrome: a clinicopathological correlation.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Neurological disorders induced by long-term exposure to organic solvents typically have a slowly progressive clinical course, which may be arrested or even reversed following discontinuation of exposure. We report an unusual case of rapidly progressive toxic leukoencephalomyelopathy in a 29-year-old

Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Antithymocyte globulin (ATG) has recently been popularized as an effective treatment in myelodysplastic syndrome (MDS). We treated 8 anemic MDS patients (refractory anemia [RA] and refractory anemia with excess blasts [RAEB-1]) with ATG (40 mg/kg/d for 4 days) and prednisone in a phase 2 trial. The

Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

We analysed the clinical features, course and response to immunosuppressive therapy in 30 patients with autoimmune disorders associated with myelodysplastic syndromes (MDS). 18 patients with MDS developed acute systemic autoimmune disorders. Common manifestations were skin vasculitis (n = 15) and

Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A 54-year-old woman with a myelodysplastic syndrome treated with high-dose chemotherapy and an allogenic bone marrow transplant developed acute cortical blindness while receiving tacrolimus (FK506). MRI showed white matter abnormalities. After discontinuation of FK506, the patient's vision returned

Bone marrow transplantation in Shwachman-Diamond syndrome: report of two cases and review of the literature.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Patients with Shwachman-Diamond syndrome (SDS) have an increased frequency of myelodysplasia and leukemic transformation. We described two patients who received allogeneic stem cell transplantation and developed multiple complications, including seizure, hyperglycemia and renal tubular acidosis. A

Neuropsychiatric disturbances in a patient with a nonmosaic isodicentric (X) (q21.32) chromosome.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A 41-year-old female patient with mental retardation and generalized epileptic seizure had a nonmosaic idic (X) (pter-q21.32::q21.32-pter) chromosome in peripheral lymphocytes and bone marrow cells. Primary amenorrhea, myelodysplastic syndrome, pigmented nevi and characteristic facial appearance

Successful electroconvulsive therapy in an elderly man with severe thrombocytopenia: case report and literature review.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Electroconvulsive therapy (ECT) is a safe and effective treatment for depression. Furthermore, modifications to ECT have made it a safe procedure for patients who were previously thought to be too ill or old to undergo the stress of convulsions. Little is known, however, of the safety of performing

Neurogenic bladder dysfunction as a signal of late failure of endoscopic third ventriculostomy in a child with spina bifida.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Endoscopic third ventriculostomy (ETV) is an option for hydrocephalus treatment in patients with Myelomeningocele mostly after a previous shunt dysfunction. Late failure of ETV is a rare event and it is traditionally associated with dramatic symptoms of intracranial hypertension. In

Severe hematologic toxicity of valproic acid. A report of four patients.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Four patients with severe cerebral palsy, mental retardation, and seizures who were treated with valproic acid showed a broad spectrum of hematologic toxicity, which included thrombocytopenia, macrocytic red cells with or without anemia, and the Pelger-Huet anomaly in the segmented neutrophils,

Treatment of acute leukemia in relapse with 4'(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Thirty-seven patients with acute leukemia in relapse were treated with a three-drug combination that included a 3- or 4-day course of AMSA with total doses ranging from 600 mg/m2 to 740 mg/m2 I.V., cytosine arabinoside 25 mg/m2 I.V. followed by 200 mg/m2 by continuous infusion daily for 5 days, and

Clinical reasoning: A 68-year-old man with a first presentation of status epilepticus.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A 64-year-old man with transfusion-dependent myelodysplastic syndrome (MDS), hypertension, chronic obstructive pulmonary disease, hypothyroidism, blindness from treated syphilitic chorioretinitis, and no prior seizure history presented in generalized status epilepticus. His daily home medication

Meropenem -valproic acid interaction in patients with cefepime-associated status epilepticus.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Two case reports of rapid decreases in valproic acid levels after initiation of meropenem in patients who developed new-onset seizure activity during treatment with cefepime are presented. CONCLUSIONS A 60-year-old Caucasian woman with myelodysplasia was transferred to the medical

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye